...
首页> 外文期刊>Current opinion in rheumatology >The role of innate immunity in autoimmune tissue injury.
【24h】

The role of innate immunity in autoimmune tissue injury.

机译:先天免疫在自身免疫组织损伤中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE OF REVIEW: To discriminate the pathomechanims of autoimmunity from that of autoimmune tissue injury, for example, in systemic lupus erythematosus, with a special focus on the role of innate pathogen recognition receptors in lupus nephritis. RECENT FINDINGS: Toll-like receptors mediate immune activation upon the recognition of pathogens in different extracellular and intracellular compartments. Systemic lupus erythematosus appears to be one of the conditions in which self-nucleic acid formats can activate innate viral nucleic acid recognition receptors like TLR-7 or TLR-9. This process can modulate the tolerance mechanisms by activating antigen-presenting cells in lymphoid organs. This mechanism does also occur at the tissue level in tissue macrophages, dendritic cells, B cells and nonimmune cells. For example, nonimmune renal cells express a limited set of functional Toll-like receptors that trigger local cytokine and chemokine release in lupus nephritis upon Toll-like receptor activation. SUMMARY: In systemic lupus erythematosus, autoantibodies and expansion of autoreactive T cells indicate systemic autoimmunity, but organ damage involves additional mechanisms of inflammation and tissue remodelling. Targeting local release of proinflammatory cytokines, for example, by blocking Toll-like receptors or single cytokines, may enhance treatment efficacy in autoimmunity without increasing systemic immunosuppression.
机译:审查目的:区分自身免疫与自身免疫组织损伤的机制,例如在系统性红斑狼疮中,特别关注先天病原体识别受体在狼疮性肾炎中的作用。最近的发现:在不同的细胞外和细胞内区室中识别病原体后,Toll样受体介导免疫激活。系统性红斑狼疮似乎是自我核酸形式可以激活先天病毒核酸识别受体(如TLR-7或TLR-9)的条件之一。这个过程可以通过激活淋巴器官中的抗原呈递细胞来调节耐受机制。这种机制也确实在组织巨噬细胞,树突状细胞,B细胞和非免疫细胞中发生。例如,非免疫性肾细胞表达有限的功能性Toll样受体,这些受体会在Toll样受体激活后触发狼疮性肾炎中局部细胞因子和趋化因子的释放。摘要:在系统性红斑狼疮中,自身抗体和自身反应性T细胞的扩增表明系统性自身免疫,但器官损伤涉及炎症和组织重塑的其他机制。例如,通过阻断Toll样受体或单一细胞因子靶向促炎细胞因子的局部释放,可以增强自身免疫治疗的疗效,而不会增加全身免疫抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号